graft-versus-host disease (GvHD)

Tag debug info: client: {"assets":{},"datasets":{},"live":{},"projects":{},"users":{},"observable":{"assets":{},"datasets":{},"live":{},"projects":{},"users":{}}}
Now: 1770473809842
Cache Key: cqdTagPageBySlug:graft-versus-host-disease-gvhd
fetchCache[cqdTagPageBySlug:graft-versus-host-disease-gvhd].expirationTime: falsey
fetchCache[cqdTagPageBySlug:graft-versus-host-disease-gvhd]. seconds remaining: falsey
All fetchCache expiration times:
-- Key: cqdNotFoundPage, seconds remaining: 308
-- Key: cqdTagPageBySlug:non-hodgkin-lymphoma, seconds remaining: 308
-- Key: cqdPostsByTag:cqd-migrated-tag-698,1,10, seconds remaining: 379
-- Key: cqdTagPageBySlug:li-frameni-syndrome-lfs, seconds remaining: 766
-- Key: cqdPostsByTag:cqd-migrated-tag-4314,1,10, seconds remaining: 833
-- Key: cqdTagPageBySlug:ehlers-danlos-syndrome, seconds remaining: 4379
-- Key: cqdPostsByTag:cqd-migrated-tag-23781,1,10, seconds remaining: 4449
-- Key: cqdTagPageBySlug:samir-kapadia, seconds remaining: 4870
-- Key: cqdPostsByTag:cqd-migrated-tag-126,3,10, seconds remaining: 4935
-- Key: cqdTagPageBySlug:obesity, seconds remaining: 8487
-- Key: cqdPostsByTag:cqd-migrated-tag-403,4,10, seconds remaining: 8555
-- Key: cqdTagPageBySlug:alzheimers-disease-ad, seconds remaining: 9449
-- Key: cqdPostsByTag:cqd-migrated-tag-18376,1,10, seconds remaining: 9514
-- Key: cqdTagPageBySlug:endovascular-aortic-repair-evar, seconds remaining: 9661
-- Key: cqdPostsByTag:cqd-migrated-tag-23043,1,10, seconds remaining: 9734
conditions:
-- false,
-- NA,
-- NA,
-- NA
-- false
Cache miss for key cqdTagPageBySlug:graft-versus-host-disease-gvhd - retrieving from Sanity
CCCache.dataFetchCount: 6966
Cache cleanup seconds remaining: 29661

Tag: graft-versus-host disease (GvHD)

Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

Graft Failure Rates Negligible Between Patients with Haplo-Identical Donors and those with Matched Unrelated Donors Receiving Cyclophosphamide

Study Identifies Safety Concern about Bortezomib as Post-Transplant GVHD Prophylaxis in High-Risk Multiple Myeloma